Literature DB >> 7761550

Effect of pulse loading with clomipramine on EEG sleep.

D J Kupfer1, B G Pollock, J M Perel, J M Miewald, V J Grochocinski, C L Ehlers.   

Abstract

Two different initial dosing regimens with clomipramine (CMI) were used to compare early response indicators and dose strategies. Thirty-two inpatients with major depressive disorder were randomized in a double-blind protocol. The pulse-loading group received 150 and 200 mg of CMI on 2 consecutive evenings and then received a placebo for 8 days. The traditional dosing group began at 50 mg of CMI followed by gradual increases every second day until 200 mg was reached. After 10 days, both groups were placed on an adjustable dosing schedule of CMI, initially set at 200 mg, for an additional 2 weeks. Significant drug effects were noted on several sleep parameters demonstrating suppression of rapid eye movement (REM) sleep. In the pulse-loading group, drug responders were found to have a significantly faster and more robust rebound in REM sleep than nonresponders. Both measures of REM activity and REM sleep time showed a significant difference between the groups. In addition, a significant correlation was found between falling levels of the desmethylclomipramine metabolite of CMI and REM sleep activity during the rebound phase. The clinical and theoretical implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7761550     DOI: 10.1016/0165-1781(94)90004-3

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  2 in total

1.  Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects.

Authors:  Stephan Chalon; Alvaro Pereira; Eric Lainey; François Vandenhende; John G Watkin; Luc Staner; Luc-André Granier
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

2.  Spectral EEG sleep profiles as a tool for prediction of clinical response to antidepressant treatment.

Authors:  Jean-Paul Macher; Rémy Luthringer; Luc Staner
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.